Bank of America Securities analyst Jason Gerberry projects Johnson & Johnson to report Q3 2027 sales in line with consensus but earnings below expectations, primarily due to higher-than-anticipated IPR&D dilution. This outlook, coupled with a raised price target and increased Icotyde sales projections, suggests a mixed but generally positive long-term view despite the near-term earnings concern.
This filing discloses an analyst's pre-earnings preview for Johnson & Johnson's Q3 2027 results. The key takeaway is the expectation of an earnings miss, driven by significant IPR&D dilution that consensus estimates may not fully reflect. This could lead to short-term negative pressure on JNJ shares if the earnings miss is confirmed. However, the analyst also raised the price target and significantly increased peak sales projections for Icotyde, indicating a positive long-term outlook for the company's pharmaceutical pipeline. Traders should monitor the actual earnings report for confirmation of the IPR&D impact and the company's commentary on future growth drivers like Icotyde and oncology launches.